Welcome international healthcare professionals

Welcome, this website is intended for healthcare professionals with an interest in the ECC Webcasts. By clicking the button below you are declaring and confirming that you are a healthcare professional.

You are here

Therapeutic Considerations in Advanced Renal Cell Carcinoma: A Continuum of Care

Fri 25 Sept / 14:00 - 16:00 / Hall A5

Prognostic markers for renal cell carcinoma (RCC) can support patient counseling and trial design; however, there are currently no predictive markers to guide therapy selection. Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKIs) approved for first-line treatment of advanced RCC have comparable efficacy, making tolerability and patient preference important factors. In the PISCES study, patients preferred pazopanib over sunitinib in this setting. The choice between everolimus and axitinib following prior VEGFR TKI should consider efficacy and potential for cumulative toxicity.

This Webcast and Webcast Report were supported by Novartis Oncology, all items are subject to independent peer and editorial review.

This scientific information may include data/information on investigational uses of compounds/drugs that have not yet been approved by regulatory authorities.


Search this site

Search form


Register to our E-Alert to stay informed of new clinical research and cases published on this platform.